Novartis: Entresto shows benefit in specific subgroups
(CercleFinance.com) - Swiss drugmaker Novartis said on Monday that in specific subgroups, treatment with its Entresto drug may result in greater reductions in heart failure hospitalizations and cardiovascular death compared to blood pressure drug valsartan.
The new analyses show that the treatment benefit of Entresto compared to valsartan may extend to patients with a left ventricular ejection fraction (LVEF) higher than the threshold that is traditionally used to define patients with heart failure with reduced ejection fraction (HFrEF), the group said.
In particular, Entresto reduced risk in total heart failure hospitalizations and cardiovascular death in women, compared to men, Novartis said.
Last Friday Novartis said that its new drug Adakveo has been approved by the US FDA to reduce frequency of pain crises in individuals living with sickle cell disease.
Copyright (c) 2019 CercleFinance.com. All rights reserved.
The new analyses show that the treatment benefit of Entresto compared to valsartan may extend to patients with a left ventricular ejection fraction (LVEF) higher than the threshold that is traditionally used to define patients with heart failure with reduced ejection fraction (HFrEF), the group said.
In particular, Entresto reduced risk in total heart failure hospitalizations and cardiovascular death in women, compared to men, Novartis said.
Last Friday Novartis said that its new drug Adakveo has been approved by the US FDA to reduce frequency of pain crises in individuals living with sickle cell disease.
Copyright (c) 2019 CercleFinance.com. All rights reserved.